Back to Journals » Journal of Pain Research » Volume 11

Safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate to severe pain following laparoscopic abdominal surgery

Authors Singla N, McCallum SW, Mack RJ, Freyer A, Hobson S, Du W

Received 25 January 2018

Accepted for publication 10 July 2018

Published 18 September 2018 Volume 2018:11 Pages 1901—1903

DOI https://doi.org/10.2147/JPR.S163736

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr E Alfonso Romero-Sandoval


Neil Singla,1 Stewart W McCallum,2 Randall J Mack,2 Alex Freyer,2 Sue Hobson,2 Wei Du3

1Lotus Clinical Research, Pasadena, CA, USA; 2Research and Development, Recro Pharma, Inc., Malvern, PA, USA; 3Clinical Statistics Consulting, Blue Bell, PA, USA

Postoperative pain after laparoscopic surgery is one of the major concerns of patients. Improper pain management can be associated with varied respiratory, cardiovascular, gastrointestinal, and psychological complications. Pain after laparoscopic surgery may be transient or persistent2 and opioids have traditionally been the mainstay treatment for postoperative pain.3 Increasing evidence exists to support a multimodal treatment approach for postoperative pain that reduces opioid side effects and decreases pain intensity (PI) scores.3 A proprietary nanocrystal intravenous (NIV) formulation of the non-steroidal anti-inflammatory meloxicam, a long-acting preferential cyclooxygenase-2 inhibitor, is being evaluated with the aim of providing rapid and sustained analgesia.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]